title: Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathy.
abstract: OBJECTIVE
  Increased activity of the enzyme aldose reductase in the polyol pathway, occurring with hyperglucaemia, has been implicated in the development of late diabetic complications. The effect of an aldose reductase inhibitor (Ponalrestat) on renal function in type 1 diabetes with incipient nephropathy (urinary albumin excretion rate > 20 micrograms.min-1) was evaluated.
  
  
  METHODS
  Thirty Type 1 diabetic patients (age: 34.4 +/- 3.1 yrs; diabetes duration 13.1 +/- 1.3 yrs) were treated with 600 mg of Ponalrestat per day for 3 months using a randomized double blind placebo controlled crossover design. Urinary albumin excretion rate and glomerular filtration rate were measured.
  
  
  RESULTS
  Twenty three patients completed the entire study. Compared to placebo, there was no significant change in urinary albumin excretion rate and glomerular filtration rate during the Ponalrestat treatment period. Blood pressure and HbA1 were also unchanged during the placebo and Ponalrestat periods. Treatment with Ponalrestat appeared to be safe and there were no side effects.
  
  
  CONCLUSIONS
  We conclude that three months aldose reductase inhibition with Ponalrestat had no effect on urinary albumin excretion rate and glomerular filtration rate in Type 1 diabetic patients with incipient nephropathy.
authors.affiliation: Department of Endocrinology and Metabolic Diseases, Hôtel-Dieu, Nantes, France.
authors.forename: S
authors.initials: S
authors.lastname: Ranganathan
authors.forename: M
authors.initials: M
authors.lastname: Krempf
authors.forename: E
authors.initials: E
authors.lastname: Feraille
authors.forename: B
authors.initials: B
authors.lastname: Charbonnel
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000652:urine*; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000652:urine; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000652:urine; D004311:Double-Blind Method; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D008297:Male; D008875:Middle Aged; D010793:Phthalazines / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D010793:Phthalazines; C042829:ponalrestat; D000449:Aldehyde Reductase